Pear Therapeutics to go public via merger with Thimble Point SPAC

Pear Therapeutics, a developer of prescription digital therapeutics, has agreed to go public via a merger with Thimble Point Acquisition Corp, a blank check company whose management team is associated with the Pritzker Vlock Family Office.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this